Anavex Life Sciences to Present at the 22nd Annual Needham Virtual Healthcare Conference 2023
NEW YORK, April 10, 2023 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage...
Cancer
Mainz Biomed Provides Full Year 2022 Financial Results
ColoAlert Revenue Increases 130% Year over Year Year End Cash Balance of $17.1 Million BERKELEY, Calif. and MAINZ, Germany, April...
OBI Pharma Announces Poster Presentations at AACR 2023 Annual Meeting for OBI-999 combination synergy with checkpoint inhibitor as well as Globo H-targeted CAR T-cell immunotherapy
Poster Presentations to highlight the latest research on OBI-999’s (anti-Globo H ADC) synergistic anti-tumor effect in combination with pembrolizumab and...
Molecular Templates Announces Partial Clinical Hold for Phase 1 Study of MT-0169
Partial hold based on previously disclosed cardiac events at 50 mcg/kg cohort; FDA to review safety data in lower dose...
Oncocyte Announces Publication of DetermaIO Results from AtezoTRIBE Study in Metastatic Colorectal Cancer
IRVINE, Calif., April 07, 2023 (GLOBE NEWSWIRE) -- Oncocyte Corporation (Nasdaq: OCX), a precision diagnostic company, today announces the peer-reviewed...
One Community, One Question: What Is Your #MYelomaSTORY?
The International Myeloma Foundation Reached Over 41 Million in More Than 45 Countries During 2023 Myeloma Action Month!STUDIO CITY, Calif.,...
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to...
Acceptance of CPP-1X (DFMO) Abstract for Poster Presentation at Endocrine Society Meeting
MINNEAPOLIS, April 06, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics...
Ocean Biomedical (NASDAQ: OCEA) Will Target Pulmonary Fibrosis Discoveries as Novel Treatments of Hermansky-Pudlak Syndrome
On Hermansky-Pudlak Syndrome (HPS) Awareness Day, Ocean Biomedical announces a commitment to developing viable treatment options for HPS-1 and HPS-4...
EDAP Announces Regulatory Clearance of ExactVu Micro-Ultrasound in Japan
Allows for market launch of the only micro-ultrasound platform for precision prostate biopsies LYON, France, April 6, 2023 -- EDAP...
HTG Technology Featured in Numerous Scientific Posters at the AACR Annual Meeting April 16-19
TUCSON, Ariz., April 06, 2023 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a platform-based life science tools...
Revolution Medicines to Present Preclinical Data at the Upcoming American Association for Cancer Research Annual Meeting 2023
REDWOOD CITY, Calif., April 06, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted...
TransCode Therapeutics to present at AACR Annual Meeting 2023
BOSTON, April 06, 2023 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA Oncology Company™ committed to more effectively treating...
Scilex Holding Company Announces Postponement of Annual Meeting of Stockholders
PALO ALTO, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex”), a subsidiary of Sorrento Therapeutics,...
Corcept Therapeutics Announces Final Results of Tender Offer
MENLO PARK, Calif., April 05, 2023 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (Nasdaq: CORT), a commercial-stage company engaged in the...
Celularity Inc. Announces $6 Million Registered Direct Offering
FLORHAM PARK, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a biotechnology company developing placental-derived allogeneic...
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
NEW YORK, April 05, 2023 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB) a commercial-stage biopharmaceutical...
Immuneering to Present Initial Phase 1 Pharmacokinetic, Pharmacodynamic Modeling and Safety Data for Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2023
- Investor call to be held at 9:00 a.m. ET on April 18, 2023 -CAMBRIDGE, Mass., April 05, 2023 (GLOBE...
Sunshine Biopharma Reports Full Year Ended December 31, 2022 Financial Results and Provides Corporate Update
MONTREAL, April 05, 2023 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM”), a pharmaceutical company offering and researching life-saving medicines...
BioAdaptives, Inc. (OTC BDPT) Announces New Appointment to the Board of Directors – Internationally Acclaimed Health Scientist, Author and Patent Holder, Dr. Yaguang Liu
LAS VEGAS, NV, April 05, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – BioAdaptives, Inc. (OTCMkts: BDPT) announced today the appointment...